{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:50:25Z","timestamp":1777531825803,"version":"3.51.4"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2014,3,19]],"date-time":"2014-03-19T00:00:00Z","timestamp":1395187200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Interv Card Electrophysiol"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s10840-014-9888-9","type":"journal-article","created":{"date-parts":[[2014,3,18]],"date-time":"2014-03-18T07:12:06Z","timestamp":1395126726000},"page":"33-38","source":"Crossref","is-referenced-by-count":35,"title":["Safety of new oral anticoagulants for patients undergoing atrial fibrillation ablation"],"prefix":"10.1007","volume":"40","author":[{"given":"Gevorg","family":"Stepanyan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nitish","family":"Badhwar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Randall J.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gregory M.","family":"Marcus","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byron K.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zian H.","family":"Tseng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vasanth","family":"Vedantham","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Olgin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melvin","family":"Scheinman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edward P.","family":"Gerstenfeld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,3,19]]},"reference":[{"key":"9888_CR1","doi-asserted-by":"crossref","first-page":"2N","DOI":"10.1016\/S0002-9149(98)00583-9","volume":"82","author":"WB Kannel","year":"1998","unstructured":"Kannel, W. B., Wolf, P. A., Benjamin, E. J., & Levy, D. (1998). Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. The American Journal of Cardiology, 82, 2N\u20139N.","journal-title":"The American Journal of Cardiology"},{"issue":"2","key":"9888_CR2","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.jacc.2010.10.001","volume":"57","author":"L Wann","year":"2011","unstructured":"Wann, L., Curtis, A., January, C. T., Ellenbogen, K., Lowe, J., Estes, M., et al. (2011). 2011 ACCF\/AHA\/HRS Focused update on the management of patients with atrial fibrillation (updating the 2006 guideline): a report of the American College of Cardiology Foundation\/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 57(2), 223\u2013242.","journal-title":"Journal of the American College of Cardiology"},{"issue":"3","key":"9888_CR3","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1093\/eurheartj\/ehs314","volume":"34","author":"M Coppens","year":"2013","unstructured":"Coppens, M., Eikelboom, J., Hart, R., Yusuf, S., Lip, G., Dorian, P., et al. (2013). The CHA2DS2-VASc score identifies those patients with atrial fibrillation and a CHADS2 score of 1 who are unlikely to benefit from oral anticoagulant therapy. European Heart Journal, 34(3), 170\u2013176.","journal-title":"European Heart Journal"},{"key":"9888_CR4","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., et al. (2009). Dabigitran versus warfarin in patients with atrial fibrillation. The New England Journal of Medicine, 361, 1139\u20131151.","journal-title":"The New England Journal of Medicine"},{"issue":"10","key":"9888_CR5","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","volume":"385","author":"MR Patel","year":"2011","unstructured":"Patel, M. R., Mahaffey, K. W., Garg, J., the ROCKET AF Steering Committee, for the ROCKET AF Investigators, et al. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. The New England Journal of Medicine, 385(10), 883\u2013891.","journal-title":"The New England Journal of Medicine"},{"key":"9888_CR6","doi-asserted-by":"crossref","unstructured":"Calkins, H., Kuck, K., Cappato, R., Brugada, J., Camm, J., Chen, S., et al. (2012). 2012 HRS\/EHRA\/ECAS Expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research. J Interv Card Electrophysiol 33, 171\u2013257.","DOI":"10.1007\/s10840-012-9672-7"},{"key":"9888_CR7","doi-asserted-by":"crossref","unstructured":"Hussein, A. A., Martin, D. O., Saliba, W., Patel, D., Karim, S., Batal, O., et al. (2009 Oct). Radiofrequency ablation of atrial fibrillation under therapeutic international normalized ratio: a safe and efficacious periprocedural anticoagulation strategy. Heart Rhythm, 6(10), 1425\u20131429.","DOI":"10.1016\/j.hrthm.2009.07.007"},{"key":"9888_CR8","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1161\/CIR.0b013e318214876d","volume":"123","author":"V Fuster","year":"2011","unstructured":"Fuster, V., Ryden, L., Cannom, D., Crijns, H., Curtis, A., Ellenbogen, K., et al. (2011). 2011 ACCF\/AHA\/HRS Focused updates incorporated into the ACC\/AHA\/ESC 2006 guidelines for the management of patients with atrial fibrillation. Circulation, 123, e269\u2013e36.","journal-title":"Circulation"},{"key":"9888_CR9","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.jacc.2011.12.014","volume":"59","author":"D Lakkireddy","year":"2012","unstructured":"Lakkireddy, D., Reddy, Y. M., Di Biase, L., et al. (2012). Feasibility and safety of dabigatran versus warfarin for peri-procedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. Journal of the American College of Cardiology, 59, 956\u2013967.","journal-title":"Journal of the American College of Cardiology"},{"key":"9888_CR10","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1540-8167.2011.02175.x","volume":"23","author":"RA Winkle","year":"2012","unstructured":"Winkle, R. A., Mead, R. H., Engel, G., Kong, M. H., & Patrawala, R. A. (2012). The use of dabigatran immediately after atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, 23, 264\u2013268.","journal-title":"Journal of Cardiovascular Electrophysiology"},{"key":"9888_CR11","doi-asserted-by":"crossref","unstructured":"Snipelisky, D., Kauffman, C., Prussak, K., Johns, G., Venkatachalam, K., & Kusumoto, F. (2012 Oct). A comparison of bleeding complications post-ablation between warfarin and dabigatran. Journal of Interventional Cardiac Electrophysiology, 35(1), 29\u201333.","DOI":"10.1007\/s10840-012-9708-z"},{"issue":"4","key":"9888_CR12","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.hrthm.2012.12.011","volume":"10","author":"JS Kim","year":"2013","unstructured":"Kim, J. S., She, F., Jongnarangsin, K., Chugh, A., Latchamsetty, R., Ghanbari, H., et al. (2013). Dabigatran vs warfarin for radiofrequency catheter ablation of atrial fibrillation. Heart Rhythm, 10(4), 483\u2013489.","journal-title":"Heart Rhythm"},{"issue":"3","key":"9888_CR13","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1007\/s10840-013-9793-7","volume":"37","author":"DW Kaiser","year":"2013","unstructured":"Kaiser, D. W., Streur, M. M., Nagarakanti, R., Whalen, S. P., & Ellis, C. R. (2013). Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter. Journal of Interventional Cardiac Electrophysiology, 37(3), 241\u2013247.","journal-title":"Journal of Interventional Cardiac Electrophysiology"},{"key":"9888_CR14","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/pace.12036","volume":"36","author":"T Nin","year":"2013","unstructured":"Nin, T., Sairaku, A., Yoshida, Y., Kamiya, H., et al. (2013). A randomized controlled trail of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation. PACE, 36, 172\u2013179.","journal-title":"PACE"},{"key":"9888_CR15","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1111\/jce.12143","volume":"24","author":"W Maddox","year":"2013","unstructured":"Maddox, W., Kay, G. N., Yamada, T., et al. (2013). Dabigatran versus warfarin therapy for uninterrupted oral anticoagulation during atrial fibrillation ablation. Journal of Cardiovascular Electrophysiology, 24, 861\u2013865.","journal-title":"Journal of Cardiovascular Electrophysiology"},{"key":"9888_CR16","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1161\/CIRCEP.113.000320","volume":"6","author":"M Bassiouny","year":"2013","unstructured":"Bassiouny, M., Saliba, W., Rickard, J., et al. (2013). Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circulation. Arrhythmia and Electrophysiology, 6, 460\u2013466.","journal-title":"Circulation. Arrhythmia and Electrophysiology"},{"key":"9888_CR17","doi-asserted-by":"crossref","unstructured":"Eitel, C., Koch, J., Sommer, P., John, S., Kircher, S., Bollmann, A., Arya, A., Piorkowski, C., Hindricks, G., (2013).Novel oral anticoagulants in a real-world cohort of patients undergoing catheter ablation of atrial fibrillation. Europace May 22. (Epub ahead of print).","DOI":"10.1093\/europace\/eut128"},{"key":"9888_CR18","unstructured":"Lakkireddy, D., Reddy, M., Swarup, V., Baqdunes, M., Mansour, M., Chaloub, F., Ruskin, J., DiBiase, L., Vallakatti, A., Janga, P., Umbarger, L., Sanchez, J., Burkhardt, D., Horton, R., Reddy, V. A, D\u2019Avila, Atkins, D., Bommana, S., Natale, A., (2013) Uninterrupted rivaroxaban vs. warfarin for periprocedural anticoagulation during atrial fibrillation ablation: a multicenter experience. Heart Rhythm. May ;10(5)S240. (Abstract)."}],"container-title":["Journal of Interventional Cardiac Electrophysiology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-014-9888-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10840-014-9888-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10840-014-9888-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,8]],"date-time":"2019-08-08T15:17:13Z","timestamp":1565277433000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10840-014-9888-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,19]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["9888"],"URL":"https:\/\/doi.org\/10.1007\/s10840-014-9888-9","relation":{},"ISSN":["1383-875X","1572-8595"],"issn-type":[{"value":"1383-875X","type":"print"},{"value":"1572-8595","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,3,19]]}}}